Join
Live feed
·
PRReleasevia Quantisnow
Regeneron Pharmaceuticals Inc. logo

Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab

ByQuantisnow·Wall Street's wire, on your screen.
REGN· Regeneron Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track REGN (Regeneron Pharmaceuticals Inc.) and more on Quantisnow.